3.5.1.89 (1R,2R)-1-O-(2-acetylamino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) competitive 204488 3.5.1.89 (1R,2R)-1-O-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) - 204489 3.5.1.89 (1R,2R)-1-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) - 204490 3.5.1.89 (1R,2R)-1-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) - 204491 3.5.1.89 (1R,2R)-2-((2-deoxy-2-[(hydroxycarbamoyl)amino]-beta-D-glucopyranosyl)oxy)cyclohexyl octadecyl phosphate - 206566 3.5.1.89 (1R,2R)-2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate - 204493 3.5.1.89 (1R,2R)-2-[(2-acetylamino-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate - 204494 3.5.1.89 (1R,2R)-2-[(2-amino-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate - 204495 3.5.1.89 (1R,2R)-2-[(2-amino-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate - 204496 3.5.1.89 (1R,2R,3S,4R,5R,6R)-2-([2-deoxy-2-[(hydroxycarbamoyl)amino]-alpha-D-glucopyranosyl]oxy)-3,4,5,6-tetrahydroxycyclohexyl octadecyl hydrogen phosphate - 169853 3.5.1.89 (1R,2S,3R,4R,5R)-4-(prop-2-en-1-yl)-6,8-dioxabicyclo[3.2.1]octane-2,3-diyl diacetate - 169861 3.5.1.89 (2R)-3-{[{[(1R,2R,3S,4R,5R,6R)-2-{[2-(carbamoylamino)-2-deoxy-alpha-D-glucopyranosyl]oxy}-3,4,5,6-tetrahydroxycyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane-1,2-diyl dihexadecanoate - 169854 3.5.1.89 1,3,4,6-tetra-O-acetyl-2-C-allyl-2-deoxy-alpha-D-glucopyranose - 169844 3.5.1.89 1,3,4,6-tetra-O-acetyl-2-C-carboxymethyl-2-deoxy-alpha-D-glucopyranose - 169846 3.5.1.89 1,3,4,6-tetra-O-acetyl-2-deoxy-2-C-formylmethyl-alpha-Dglucopyranose - 169845 3.5.1.89 1,5-anhydro-2-(carboxymethyl)-2-deoxy-D-glucitol - 88082 3.5.1.89 1,5-anhydro-2-C-(carboxymethyl N-hydroxyamide)-2-deoxy-D-glucitol - 169839 3.5.1.89 1,5-anhydro-2-C-carboxymethyl-2-deoxy-D-glucitol - 169838 3.5.1.89 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-phenyl-D-glucitol - 169855 3.5.1.89 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol - 88084 3.5.1.89 1,5-anhydro-3-O-benzoyl-2-C-carboxymethyl-2-deoxy-D-glucitol - 169837 3.5.1.89 1,5-anhydro-3-O-benzyl-2-(carboxymethyl)-2-deoxy-D-glucitol - 88081 3.5.1.89 1,5-anhydro-3-O-benzyl-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol - 88083 3.5.1.89 1,5-anhydro-3-O-benzyl-4,6-O-benzylidene-2-(carboxymethyl)-2-deoxy-D-glucitol - 169857 3.5.1.89 1,5-anhydro-3-O-benzyl-4,6-O-benzylidene-2-[2-[(benzyloxy)amino]-2-oxoethyl]-2-deoxy-D-glucitol - 169859 3.5.1.89 1,5-anhydro-4,6-O-benzylidene-2-(carboxymethyl)-2-deoxy-D-glucitol - 169858 3.5.1.89 1,5-anhydro-4,6-O-benzylidene-2-deoxy-2-prop-2-en-1-yl-D-glucitol - 169856 3.5.1.89 1,5-anhydro-4,6-O-benzylidene-2-[2-[(benzyloxy)amino]-2-oxoethyl]-2-deoxy-D-glucitol - 169860 3.5.1.89 1-acetyl-N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]piperidine-4-carboxamide 40% inhibition at 1 mM 204818 3.5.1.89 1-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}-2-hydroxyethan-1-one - 204858 3.5.1.89 2-(2,4-dichlorophenoxy)-N-hydroxyacetamide - 204900 3.5.1.89 2-(carboxymethyl)-2-deoxy-D-glucopyranose - 88085 3.5.1.89 2-C-carboxymethyl-2-deoxy-D-glucopyranose - 169840 3.5.1.89 2-deoxy-2-ureido-D-galactosylalpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol suicide inhibitor, 50% inihibition at 0.0002 mM 117273 3.5.1.89 2-deoxy-2-ureido-D-glucosyl-alpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol 50% inhibition between 0.0001 and 0.001 mM 54477 3.5.1.89 2-deoxy-2-ureido-D-glucosyl-alpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol 50% inhibition at 8 nM 54477 3.5.1.89 2-deoxy-2-ureido-D-glucosyl-beta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol 50% inhibition at about 8 nM 118307 3.5.1.89 2-deoxy-2-ureido-D-glucosylalpha1-6-D-(2-O-octyl)myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol 50% inhibition at about 8 nM 118308 3.5.1.89 2-deoxy-2-ureido-D-glucosylbeta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol suicide inhibitor, 50% inihibition at 0.0002 mM 117272 3.5.1.89 2-hydroxybenzoic acid 97% inhibition at 1 mM 5097 3.5.1.89 3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-N-hydroxypropanamide - 205097 3.5.1.89 4-(2,4-dichlorophenoxy)-N-hydroxybutanamide - 205111 3.5.1.89 4-bromo-N,2-dihydroxybenzamide 86% inhibition at 1 mM 205160 3.5.1.89 4-bromo-N-hydroxybenzamide 9.6% inhibition at 1 mM 205161 3.5.1.89 5-((tert-butoxycarbonyl)amino)-2-hydroxybenzoic acid - 206561 3.5.1.89 5-amino-N-(benzyloxy)-2-hydroxybenzamide - 206563 3.5.1.89 5-benzamido-N,2-dihydroxybenzamide 96% inhibition at 1 mM 205283 3.5.1.89 5-[(cyclohexanecarbonyl)amino]-N,2-dihydroxybenzamide 99% inhibition at 1 mM 205329 3.5.1.89 EDTA complete inhibition at 10 mM, the enzyme irreversibly loses activity upon incubation with a metal chelator 21 3.5.1.89 ethambutol docking study, the effective enzyme inhibitor may be useful in the treatment of African sleeping sickness 30726 3.5.1.89 metaraminol docking study, the effective enzyme inhibitor may be useful in the treatment of African sleeping sickness 247554 3.5.1.89 additional information not inhibitory up to 0.1 mM: 2-deoxy-2-ureido-D-glucosyl-beta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol, 2-deoxy-2-ureido-D-glucosylalpha1-6-D-(2-O-octyl)myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol 2 3.5.1.89 additional information treatment with EDTA consistently causes up to 2% reduction in activity, the activity is not significantly affected by treatment with 1,10-phenanthroline 2 3.5.1.89 additional information inhibitor identification via zinc binding fragment screening, structure activity relationship, hydroxamic acid and 2-OH are essential for potency, substitution is tolerated at the 4- and 5-positions. No inhibition by 2-bromo-N-hydroxybenzamide and 2-amino-N-hydroxybenzamide 2 3.5.1.89 additional information (1R,2R)-1-O-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) is neither a substrate nor an inhibitor 2 3.5.1.89 additional information inhibitor search by structural based virtual screening (SBVS), molecular modeling, and docking study, overview 2 3.5.1.89 N,2-dihydroxy-5-(4-methylbenzamido)benzamide 62% inhibition at 1 mM 205476 3.5.1.89 N,2-dihydroxy-5-(octadecanoylamino)benzamide 25% inhibition at 1 mM 205477 3.5.1.89 N,N-diethylethanaminium (1R,2R)-2-(2-acetamido-3-hydroxypropoxy)cyclohexyl octadecyl phosphate - 205479 3.5.1.89 N,N-diethylethanaminium 1-D-2-[(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)oxy]-myo-inosityl octadecyl phosphate - 205480 3.5.1.89 N-((1R,2R)-2-[(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl)octadecane-1-sulfonamide - 206565 3.5.1.89 N-((1R,2R)-2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl)octadecane-1-sulfonamide - 206564 3.5.1.89 N-(1R,2R)-2-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexyloctadecane-1-sulphonamide - 205492 3.5.1.89 N-(1R,2R)-2-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-cyclohexyloctadecane-1-sulphonamide - 205493 3.5.1.89 N-dimethyl-D-glucosyl-phosphatidylinositol 0.001 mM, complete inhibition 118306 3.5.1.89 N-hydroxy-N'-(4-methoxyphenyl)urea - 205610 3.5.1.89 N-hydroxybenzamide 25% inhibition at 1 mM 205639 3.5.1.89 N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]-2H-1,3-benzodioxole-5-carboxamide 86% inhibition at 1 mM 205767 3.5.1.89 N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]oxane-4-carboxamide 56% inhibition at 1 mM 205768 3.5.1.89 N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl][1,1'-biphenyl]-4-carboxamide 75% inhibition at 1 mM 205769 3.5.1.89 phenyl 2-(carbamoylamino)-2-deoxy-1-thio-beta-D-glucopyranoside - 88086 3.5.1.89 phenyl 2-(carboxymethyl)-2-deoxy-1-thio-alpha-D-glucopyranoside - 42121 3.5.1.89 phenyl 2-(N-aminocarbonyl)amino-2-deoxy-1-thio-beta-Dglucopyranoside - 169843 3.5.1.89 phenyl 2-amino-2-deoxy-1-thio-beta-D-glucopyranoside - 169862 3.5.1.89 phenyl 2-C-carboxymethyl-2-deoxy-1-thio-alpha-Dglucopyranoside - 169841 3.5.1.89 phenyl 2-C-carboxymethyl-2-deoxy-1-thio-beta-Dglucopyranoside - 169842 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-C-allyl-2-deoxy-1-thio-alpha-D-glucopyranoside - 169847 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-C-allyl-2-deoxy-1-thio-beta-D-glucopyranoside - 169848 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-C-carboxymethyl-2-deoxy-1-thio-alpha-D-glucopyranoside - 169851 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-C-carboxymethyl-2-deoxy-1-thio-beta-D-glucopyranoside - 169852 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-C-formylmethyl-1-thio-alpha-D-glucopyranoside - 169849 3.5.1.89 phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-C-formylmethyl-1-thio-beta-D-glucopyranoside - 169850 3.5.1.89 salicylic hydroxamic acid enzyme inhibitor with high ligand efficiency, proposed mode of action, overview 49414 3.5.1.89 tert-butyl (3-((benzyloxy)carbamoyl)-4-hydroxyphenyl)carbamate - 206562 3.5.1.89 triethylammonium 1R,2R-1-O-[2-C-(carboxymethyl N-hydroxyamide)-2-deoxy-beta-D-glucopyranosyl]-cyclohexanediol 2-(n-octadecylphosphate) - 88080 3.5.1.89 triethylammonium trans-2-(2-amino-3-hydroxypropoxy)-cyclohexyl n-octadecyl phosphate - 205857